welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

L-citrulline and Metformin in Becker’s Muscular Dystrophy

key information

study id #: NCT02018731

condition: Becker's Muscular Dystrophy (BMD)

status: completed


The purpose of the study is to compare the effects of L-citrulline and metformin and their combination therapy on muscle function and force in patients with Becker muscular dystrophy (BMD).

intervention: Metformin and Metformin & L-Citrulline, L-Citrulline and Metformin & L-Citrulline

mechanism of action: Muscle cell engery regulators to prevent muscle loss

results: https://clinicaltrials.gov/ct2/show/results/NCT02018731

last updated: November 22, 2018

study details

start date: June 2013

estimated completion: December 2015

phase of development: Phase 2

size / enrollment: 20

study description:
This is a single center, not-randomized open study. The study medication consists of L-citrulline and metformin administered orally; 5g citrulline and 500mg metformin tablets will be given 3 times daily.
Half of the patients will be treated with metformin during the first 6 weeks of the study. The other patients will receive initially L-citrulline for 6 weeks, before all patients will be treated with the combination therapy (metformin and L-citrulline) for another 6 week period.
The study lasts 12 weeks and includes the screening visit and 3 further visits at baseline, week 6 and week 12.

primary outcomes:

  • Mean change of motor function measure (MFM) D1 subscore after 6 and 12 weeks [ Time Frame: week 6 and week 12 ]

secondary outcomes:

  • MFM total score and six minute walking distance (6MWD) [ Time Frame: week 6 and week 12 ]
  • Change of muscle fat content (MFC) (assessed by MRI) [ Time Frame: week 6 and week 12 ]
  • Change of muscle metabolism (assessed by dual energy x-ray absorptiometry (DEXA) and indirect calorimetry) [ Time Frame: week 6 and week 12 ]
  • Change of laboratory parameters (oxidative and nitrosative stress) [ Time Frame: week 6 and week 12 ]

inclusion criteria:
• 18 years or older
• Molecular or immunohistochemical diagnosis of BMD
• ambulant at the time point of screening

exclusion criteria:
• Participation in another therapeutic BMD study within the last 3 months
• Use of L-Arginine, L-Citrulline or Metformin within the last 3 months
• Other chronic disease or relevant limitation of renal, liver, heart function according to discretion of investigator
• known hypersensitivity to L-citrulline or metformin

study contacts

sponsor: University Hospital, Basel, Switzerland

investigators: Dirk Fischer, MD

locations: Switzerland